Atea Pharmaceuticals, Inc. (AVIR) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is neutral — 1 Buy, 2 Hold, 1 Sell.
The consensus price target is $6.88, representing an upside of 18.6% from the current price $5.80.
Analysts estimate Earnings Per Share (EPS) of $-1.80 and revenue of $0.07B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.00 vs est $-1.80 (missed -10.9%). 2025: actual $-1.94 vs est $-1.73 (missed -12.5%). Analyst accuracy: 90%.
AVIR Stock — 12-Month Price Forecast
$6.88
▲ +18.62% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Atea Pharmaceuticals, Inc., the price target is $6.88.
The average price target represents a +18.62% change from the last price of $5.80.
AVIR Analyst Ratings
Hold
Based on 4 analysts giving stock ratings to Atea Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — AVIR
90%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.00
vs Est –$1.80
▼ 9.8% off
2025
Actual –$1.94
vs Est –$1.73
▼ 11.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — AVIR
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
